Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Pettengell, R; Johnson, H E; Lugtenburg, P J; Salar Silvestre, A; Dührsen, U; Rossi, F G; Schwenkglenks, M; Bendall, K; Szabo, Z; Jaeger, U (2012). Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer, 20(3):647-652.

Johnsen, H E; Haioun, C; Lugtenburg, P J; Salar, A; Jaeger, U; Pettengell, R; Rossi, Fg; Verhoef, G; Schwenkglenks, M; Bendall, K; Duehrsen, U (2012). The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice. Leukemia and Lymphoma, 53(5):982-984.

Haioun, C; Salar, A; Pettengell, R; Johnsen, H E; Duehrsen, U; Rossi, F G; Verhoef, G; Schwenkglenks, M; Jaeger, U; Hamilton, L; Pujol, B; Lugtenburg, P J (2011). Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leukemia and Lymphoma, 52(5):796-803.

Pfreundschuh, M; Kuhnt, E; Trümper, L; Osterborg, A; Trneny, M; Shepherd, L; Gill, D S; Walewski, J; Pettengell, R; Jaeger, U; Zinzani, P L; Shpilberg, O; Kvaloy, S; de Nully Brown, P; Stahel, R; Milpied, N; López-Guillermo, A; Poeschel, V; Grass, S; Loeffler, M; Murawski, N (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, 12(11):1013-1022.

Pettengell, R; Schwenkglenks, M (2011). Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leukemia and Lymphoma, 52(6):1133-1136.

Pettengell, R; Schwenkglenks, M; Bacon, P; Lawrinson, S; Duehrsen, U (2011). Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematological Oncology, 29(4):177-184.

Schwenkglenks, M; Pettengell, R; Jackisch, C; Paridaens, R; Constenla, M; Bosly, A; Szucs, T D; Leonard, R (2011). Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Supportive Care in Cancer, 19(4):483-490.

Schwenkglenks, M; Pettengell, R; Szucs, T D; Culakova, E; Lyman, G H (2010). Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. Journal of Hematology and Oncology, 3:27.

Pettengell, R; Bosly, A; Szucs, T D; Jackisch, C; Leonard, R; Paridaens, R; Constenla, M; Schwenkglenks, M (2008). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. British Journal of Haematology, 144(5):677-685.

Pettengell, R; Schwenkglenks, M; Leonard, R; Bosly, A; Paridaens, R; Constenla, M; Szucs, T D; Jackisch, C (2008). Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 16(11):1299-1309.

Schwenkglenks, M; Jackisch, C; Constenla, M; Kerger, J N; Paridaens, R; Auerbach, L; Bosly, A; Pettengell, R; Szucs, T D; Leonard, R (2006). Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer, 14(9):901-909.

This list was generated on Sun Aug 25 07:10:09 2019 CEST.